Compare NetApp Inc. (NTAP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? NetApp Inc. trades at $231.07 (market cap $46.31B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.8× NetApp Inc.'s market cap, and NetApp Inc. pays a 0.88% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 57 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| NTAP | VRTX | |
|---|---|---|
Market Cap | $46.31B | $128.16B |
Volume | 3,002,392 | 806,603 |
Sector | Technology | Health |
52-Week High | $235.84 | $557.96 |
52-Week Low | $94.11 | $407.37 |
Typical Hold Time | 57 Days | 120 Days |
Enterprise Value | $45.27B | $122.29B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $231.05, up 1.14% today, with a bullish technical outlook supported by moving averages and positive earnings beats in recent quarters. The company reported strong profitability with a 70.63% gross margin and 19.19% net margin for 2025, alongside strategic AI partnerships announced at INSIGHT 2026. Revenue growth is projected to reach $7.4B in 2026, though valuation ratios like a P/E of 33.3 suggest a premium.
The stock faces risks from high valuation and competitive pressures, but analyst sentiment is mixed with a consensus price target of $219.30. Upside potential hinges on execution of AI initiatives, while downside risks include market volatility and execution missteps. Institutional ownership trends and recent insider activity should be monitored for confidence.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
